https://orcid.org/0000-0001-7530-9801
References
- Ait-Daoud N, Hamby AS, Sharma S, Blevins D. 2018. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 12(1):4–10. doi:10.1097/ADM.0000000000000350
- Ciraulo DA, Barnhill JG, Boxenbaum HG, Greenblatt DJ, Smith RB. 1986. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. J Clin Pharmacol. 26(4):292–298. doi:10.1002/j.1552-4604.1986.tb03526.x
- Grigsby TJ, Howard JT, Deason RG, Haskard-Zolnierek KB, Howard K. 2022. Correlates of COVID-19 pandemic-related increases in sleep aid and anti-anxiety medication use. J Subst Use. 27(1):56–61. doi:10.1080/14659891.2021.1892221
- Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, Rasoulpoor S, Khaledi-Paveh B. 2020. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health. 16(1):1–11. doi:10.1186/s12992-020-00589-w
- SAS 2017. SAS Enterprise Enterprise Guide 7.1. Cary (NC): SAS Institute Inc.